Brief: Kronos Bio Announces Pipeline Update And P300 Kat Inhibitor Development Candidate

Kronos Bio

18/12/2023 22:16

Dec 18 (Reuters) - Kronos Bio Inc  KRON.O :
    * KRONOS BIO ANNOUNCES PIPELINE UPDATE AND P300 KAT
INHIBITOR
DEVELOPMENT CANDIDATE
    * KRONOS BIO INC - EXPECTED CASH RUNWAY MAINTAINED INTO 2026
    * KRONOS BIO INC - PHASE 1B PORTION OF PHASE 1B/2
LANRAPLENIB
STUDY IN PATIENTS WITH RELAPSED/REFRACTORY FLT3-MUTATED ACUTE
MYELOID LEUKEMIA COMPLETED
    * KRONOS BIO INC -  REVIEW OF DATA DOES NOT SUPPORT
CONTINUING
LANRAPLENIB STUDY TO PHASE 2
    * KRONOS BIO INC - NEW DEVELOPMENT CANDIDATE KB-9558
INHIBITS KAT
DOMAIN OF P300 AND THEREBY MODULATES IRF4, A KEY DRIVER OF
MULTIPLE MYELOMA
    * KRONOS BIO INC - KB-0742 CLEARED 80 MG DOSE IN DOSE
ESCALATION
PORTION OF PHASE 1/2 TRIAL
    * KRONOS BIO INC - OPEN TO FURTHER DEVELOPMENT OF
LANRAPLENIB, A
SYK INHIBITOR, WITH A PARTNER
    * KRONOS BIO INC -  KB-9558 IS CURRENTLY IN IND-ENABLING
STUDIES,
WHICH ARE EXPECTED TO BE COMPLETED IN Q4 OF 2024

Source text for Eikon:  ID:nGNX70tcPr 
Further company coverage:  KRON.O 

 ((Reuters.Briefs@thomsonreuters.com;))